Cue Biopharma is a clinical-stage biopharmaceutical company. Co.'s proprietary Immuno-Selective Targeting and Alteration of T Cells (Immuno-STAT) platform, enable Co. to restore health while avoiding the side effects of immune activation in the case of cancer and immune suppression in the case of autoimmune disease. Co. focused its internal resources on drug product candidates in its CUE-100 series of Immuno-STATs. The CUE-100 series uses the selectivity of the T cell receptor combined with rationally engineered interleukin 2 in context of the core Immuno-STAT framework for selective activation of targeted tumor-specific T cells to potentially address a range of cancers. The CUE average annual return since 2018 is shown above.
The Average Annual Return on the CUE average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CUE average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CUE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|